WallStreetZenWallStreetZen

NASDAQ: SGEN
Seagen Inc Stock

Open Broker Account
$125.24+5.88 (+4.93%)
Updated Dec 8, 2022
SGEN Price
$125.24
Fair Value Price
$128.19
Market Cap
$23.25B
52 Week Low
$105.43
52 Week High
$183.00
P/E
-36.3x
P/B
8.24x
P/S
13.56x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.86B
Earnings
-$636.77M
Gross Margin
79.2%
Operating Margin
-34.09%
Profit Margin
-34.2%
Debt to Equity
0.28
Operating Cash Flow
-$658M
Beta
0.8
Next Earnings
Feb 7, 2023
Ex-Dividend
N/A
Next Dividend
N/A

SGEN Overview

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SGEN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SGEN ($125.24) is undervalued by 2.3% relative to our estimate of its Fair Value price of $128.19 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SGEN ($125.24) is not significantly undervalued (2.3%) relative to our estimate of its Fair Value price of $128.19 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SGEN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SGEN due diligence checks available for Premium users.

Be the first to know about important SGEN news, forecast changes, insider trades & much more!

SGEN News

Valuation

SGEN fair value

Fair Value of SGEN stock based on Discounted Cash Flow (DCF)
Price
$125.24
Fair Value
$128.19
Undervalued by
2.30%
SGEN ($125.24) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SGEN ($125.24) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SGEN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SGEN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-36.3x
Industry
13.31x
Market
21.39x

SGEN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
8.24x
Industry
4.98x
SGEN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SGEN's financial health

Profit margin

Revenue
$510.3M
Net Income
-$190.8M
Profit Margin
-37.4%
SGEN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SGEN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$3.6B
Liabilities
$797.3M
Debt to equity
0.28
SGEN's short-term assets ($2.76B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SGEN's short-term assets ($2.76B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SGEN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SGEN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$85.7M
Investing
$65.0M
Financing
$18.4M
SGEN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SGEN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
SGEN$23.25B+4.93%-36.30x8.24x
ARGX$21.45B+1.34%-22.16x7.15x
BGNE$20.87B+3.83%-121.68x4.48x
RPRX$25.70B+0.47%37.13x2.47x
BMRN$19.40B+0.68%231.98x4.25x

Seagen Stock FAQ

What is Seagen's quote symbol?

NASDAQ: SGEN) Seagen trades on the NASDAQ under the ticker symbol SGEN. Seagen stock quotes can also be displayed as NASDAQ: SGEN.

If you're new to stock investing, here's how to buy Seagen stock.

What is the 52 week high and low for Seagen (NASDAQ: SGEN)?

(NASDAQ: SGEN) Seagen's 52-week high was $183.00, and its 52-week low was $105.43. It is currently -31.56% from its 52-week high and 18.79% from its 52-week low.

How much is Seagen stock worth today?

(NASDAQ: SGEN) Seagen currently has 185,664,901 outstanding shares. With Seagen stock trading at $125.24 per share, the total value of Seagen stock (market capitalization) is $23.25B.

Seagen stock was originally listed at a price of $8.50 in Mar 9, 2001. If you had invested in Seagen stock at $8.50, your return over the last 21 years would have been 1,373.41%, for an annualized return of 13.67% (not including any dividends or dividend reinvestments).

How much is Seagen's stock price per share?

(NASDAQ: SGEN) Seagen stock price per share is $125.24 today (as of Dec 8, 2022).

What is Seagen's Market Cap?

(NASDAQ: SGEN) Seagen's market cap is $23.25B, as of Dec 9, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Seagen's market cap is calculated by multiplying SGEN's current stock price of $125.24 by SGEN's total outstanding shares of 185,664,901.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.